pr Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More By xconomy.com Published On :: Fri, 08 May 2020 14:33:23 +0000 Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal. Last October, Alexion (NASDAQ: ALXN) struck a $930 million deal to acquire Achillion Pharmaceuticals, a biotech whose lead drug complements the Boston company’s […] Full Article Boston blog main Boston top stories Boulder/Denver blog main Boulder/Denver top stories Detroit blog main Detroit top stories Europe blog main Europe top stories Indiana blog main Indiana top stories National National blog main National top stories New York blog main New York top stories Raleigh-Durham blog main Raleigh-Durham top stories San Diego blog main San Diego top stories San Francisco blog main San Francisco top stories Seattle blog main Seattle top stories Texas blog main Texas top stories Wisconsin blog main Wisconsin top stories AbbVie Achillion Pharmaceuticals Akcea Therapeutics Alexion Pharmaceuticals Alnylam Pharmaceuticals andexanet alfa Antibe Therapeutics Apotex Arrowhead Pharmaceuticals AstraZeneca Avrobio Axcella Health. Newron Pharmaceuticals basal cell carcinoma BioMarin Pharmaceutical BioNtech Biotech blastic plasmacytoid dendritic cell neoplasm Bristol-myers Squibb Bruce Given cancer Cardiff Oncology Carla Poulson Celgene Cell Therapy cemiplimab Censa Pharmaceuticals Chemotherapy chlorambucil Chronic Lymphocytic Leukemia Clarametyx Biosciences Clostridium difficile COVID-19 CRISPR dapagliflozin Diagnostics DiNAQOR dry eye disease epilepsy Federal Trade Commission Ferring Pharmaceuticals FogPharma Fragile X Syndrome Gemini Therapeutics Gene Therapy Gilead Sciences Grail Incyte Innate Immune System investing Joseph Stauffer Kala Pharmaceuticals Kezar Life Sciences Kura Oncology Life Sciences lisocaptagene maraleucel Ludwig Hantson Magenta Therapeutics Marc Uknis Mark Erlander Menarini Group Microbiome microbiome drugs Myonexus Therapeutics Neurological Diseases Noreen Roth Henig Novartis Obinutuzumab Ovid Therapeutics Pfizer Portola Pharmaceuticals pravastatin Praxis Precision Medicines PTC Therapeutics rare disease drugs rebiotix Regeneron Pharmaceuticals remdesirvir Rett syndrome Sanofi Sarepta Therapeutics sarizotan Sherlock Biosciences startups Stemline Therapeutics systolic heart failure TG Therapeutics Tony Gibney TrovaGene U.S. Department of Justice ublituximab umbralisib Ventus Therapeutics Vir Biotechnology
pr Disarm Therapeutics hires Dr Alvin Shih as new President and CEO By www.pharmafile.com Published On :: Tue, 23 Jul 2019 14:46:45 +0000 Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO. The Cambridge, Mass.-based firm has set itself the task of creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central drive of neurological disease. Dr Shih brings to the role a range of experiences. Having graduated with a biology degree from Vanderbilt University in 1996, Shih joined management consultancy McKinsey where he worked as a business analyst for two years. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
pr Vertex promote chief medical officer to CEO as Jeffrey Leiden steps down By www.pharmafile.com Published On :: Thu, 25 Jul 2019 15:31:24 +0000 Dr Reshma Kewalramani has been made the new Vertex CEO. Vertex’s Chief Medical Officer Dr Kewalramani will succeed current CEO Jeffrey Leiden who has is now stepping aside from the role after seven years as Chief executive at the Boston-based firm. In stepping down Leiden will serve as executive chairman until the first quarter of 2023. Fourty-six year old Dr Kewalramani, who has been at Vertex since 2017, will thus become the first woman to head the firm. Prior to joining Vertex, Kewalramani spent more than 12 years at Amgen. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
pr Troy Robinson promoted to managing director of Chugai Pharma Europe By www.pharmafile.com Published On :: Tue, 06 Aug 2019 16:14:25 +0000 Troy Robinson has been taken on as the new managing director of Chugai Pharma Europe. Mike Crosher will succeed him in his current role as managing director of Chugai Pharma UK. Chugai Pharma Europe (CPE) has promoted Troy Robinson and Mike Crosher into the positions of managing director of CPE and managing director of the firm’s UK subsidiary, Chugai Pharma UK (CPU). read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
pr Saniona appoints Rami Levin as President and Chief Executive Officer By www.pharmafile.com Published On :: Wed, 08 Jan 2020 08:49:55 +0000 Saniona has announced that Rami Levin will take over as the Chief Executive Officer of the company as it seeks to transition into a fully-fledge biopharmaceuticals company, with a focus on rare diseases. Levin was appointed by the Board of Directors and the company’s founders. His appointment takes immediate effect. read more Full Article appointments rare diseases Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
pr Chris Thatcher to step down as President and CEO of Neuronetics By www.pharmafile.com Published On :: Mon, 09 Mar 2020 16:58:03 +0000 Neuronetics, Inc and Chris Thatcher, the President and CEO, have mutually agreed that he will step down from his positions in the company. He will provide transition services and advice to the company until 1 May 2020. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
pr Dr John C. McKew promoted to Chief Operating Officer at Lumos Pharma By www.pharmafile.com Published On :: Fri, 03 Apr 2020 15:23:02 +0000 Lumos Pharma, Inc. has promoted Dr John McKew to the position of Chief Operating Officer effective 1 April 2020. McKew is already Chief Scientific Officer and he will do both roles simultaneously. With his new role, he will lead Lumos’s clinical development plan as the company looks toward adding additional assets to its pipeline. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
pr Preparing to Go Back to the Bedside During COVID-19: A Nurse-Turned-Bioethicist Reflects By blog.petrieflom.law.harvard.edu Published On :: Thu, 30 Apr 2020 16:30:23 +0000 This was the first time in a long time that I’ve renewed my nursing license with the thought that I might need it — that I might be needed. The post Preparing to Go Back to the Bedside During COVID-19: A Nurse-Turned-Bioethicist Reflects appeared first on Bill of Health. Full Article Bioethics Emily Largent Featured Patient Care Public Health coronavirus coronavirus pandemic COVID-19 COVID19 emily largent nursing public health temporary practice permit
pr How States are Protecting Health Care Providers from Legal Liability in the COVID-19 Pandemic By blog.petrieflom.law.harvard.edu Published On :: Tue, 05 May 2020 17:30:58 +0000 Clinicians and policymakers alike are raising the alarm about potential legal liability for following crisis standards of care during the COVID-19 pandemic. The post How States are Protecting Health Care Providers from Legal Liability in the COVID-19 Pandemic appeared first on Bill of Health. Full Article Health Law Policy Liability Patient Care Professional Regulation coronavirus coronavirus pandemic COVID-19 COVID19 crisis standards of care Health Law legal liability Malpractice Medical Malpractice valerie gutmann koch
pr Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson By blog.petrieflom.law.harvard.edu Published On :: Thu, 07 May 2020 14:55:20 +0000 In this video explainer, Christopher Robertson discusses the Right to Try Act and off-label use of pharmaceuticals with Alison Bateman-House. The post Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson appeared first on Bill of Health. Full Article Christopher Robertson FDA Health Law Policy Off-Label Use Pharmaceuticals Public Health alison bateman-house christopher robertson coronavirus coronavirus pandemic COVID-19 COVID19 off-label use Regulation right to try
pr For A New Device To Treat Maternal Bleeding, A Young Entrepreneur’s Big Step Was Passing The Torch By www.forbes.com Published On :: Thu, 20 Sep 2018 13:00:00 +0000 This morning, Alydia Health, a tiny Menlo Park, Calif., startup co-founded by a 21-year-old woman, announced that it has secured $10 million in funding to test a medical device to prevent mothers from bleeding to death after childbirth. Full Article byline=Matthew Herper
pr Three Things to Look for in a Patient Assistance Program By feeds.feedblitz.com Published On :: Fri, 20 Mar 2020 11:30:00 +0000 Today’s guest post comes from Rob Brown, Vice President and General Manager of RxCrossroads by McKesson and Biologics by McKesson.Rob discusses the importance of access, adherence, and affordability for specialty therapy patients who are uninsured, underinsured, or low-income. He describes three criteria companies should use to evaluate patient assistance program solutions.Click here to learn more about program pharmacy solutions for biopharma from RxCrossroads by McKesson.Read on for Rob’s insights.Read more » Full Article Guest Post Sponsored Post
pr Informa Connect-CBI’s 22nd Annual Medicaid and Government Pricing Congress By feeds.feedblitz.com Published On :: Mon, 23 Mar 2020 11:30:00 +0000 Informa Connect-CBI’s 22nd Annual Medicaid and Government Pricing CongressMay 19-21, 2020 | Orlando, FLwww.cbinet.com/medicaidandgovernmentExclusive Offer: Register by April 10th and save $500* (mention promo code MDCDC5).With a volatile healthcare system combined with an election year upon us, the stakes are incredibly high for life sciences manufacturers. Staying on the pulse of industry trends, policies and regulations has never been more critical. The 22nd Annual Medicaid and Government Pricing Congress delivers critical updates and industry best practices to effectively contract, report and comply with state and federal healthcare programs. Gain timely, up-to-the-minute insights on:State Invoicing and DisputesGTN ModelsInnovative Contracting StrategiesState Price Transparency and Reporting Requirements340B Oversight and CompliancePreparing, Negotiating and Implementing FSS ContractsBona Fide Service Fees and FMVAnd many other critical topicsDownload the complete program agenda.The 2020 agenda features 75+ speakers and 50+ sessions customizable by company type and size, as well as 10 hours of dedicated networking. Bio/pharma, regulatory and government experts representing HHS, Pfizer, Daiichi Sankyo, Sobi, Maryland Department of Health, BMS, Jazz, Novartis, Amneal, J&J, Sunovion, Gilead, VA, Granard, Insmed, UCB, Alnylam, Louisiana Department of Health, AstraZeneca, CMS, CSL Behring, Astellas, Lilly, Oklahoma Healthcare Authority, Theravance, Indivior, Sandoz, Alvogen, Takeda, OIG, AMAG, Aimmune, Exelixis, South Dakota Department of Healthcare Services, Regeneron, Sun Pharma, Teva and many others are set to drive the dynamic dialogue. Drug Channels readers can register today and use promo code MDCDC5 to save $500.*Discount offer valid through 4/10/2020; applies to standard rates only and may not be combined with other offers, categories, promotions or applied to an existing registration. Offer not valid on workshop-only or non-profit registrations.The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. Full Article Sponsored Post
pr Drug Channels News Roundup, March 2020: Sanofi’s Gross-to-Net Bubble, Drug Pricing Findings, Amazon Replaces Express Scripts, and Drug Channels Video By feeds.feedblitz.com Published On :: Tue, 31 Mar 2020 11:30:00 +0000 First, let me say thank you to all of the healthcare workers who are putting themselves at risk during this crisis.As I noted last week, many of the crucial issues for our healthcare system will remain after we all get through this challenging period. In that regard, here’s a look at some noteworthy news from the past month: Sanofi discloses new data about insulin pricesExcellent new academic research on list vs. net drug prices Three notable researchers overturn their earlier research on drug costsAmazon switches PBM vendors for some of its employeesPlus, we unveil the teaser trailer for Drug Channels Video!P.S. Join the more than 9,000 followers of my daily links to neat stuff at @DrugChannels on Twitter. My recent tweets have highlighted such topics as:How GoodRx shares patients’ prescription data2019 drug trend at Prime TherapeuticsControversy about the independent pharmacy marketA new $5 generic mail order program, Medicare Part D reformRetail pharmacy’s futureJob openings at Amazon Frozen cookie doughAnd much more!I have also been tweeting many under-the-radar stories about how the coronavirus affects drug channels.Read more » Full Article Benefit Design Costs/Reimbursement Gross-to-Net Bubble PBMs
pr Four Unexpected Ways that the COVID-19 Medicaid Boom Will Affect PBM and Pharmacy Profits By feeds.feedblitz.com Published On :: Wed, 15 Apr 2020 11:00:00 +0000 The U.S. economy is in a medically-induced coma. Unemployment is soaring. Companies are teetering on the brink of bankruptcy. It is unclear when our lives will return to their pre-pandemic state.One thing seems apparent: As people lose jobs and health insurance, Medicaid enrollment will jump, perhaps by as much as 20% to 30%. This will have profound implications for the drug channel.Today, I focus on how this increase will affect retail pharmacies and pharmacy benefit managers (PBMs). Below, I review Medicaid enrollment trends, how states manage prescriptions, and the factors driving the coming boom in Medicaid enrollment. As I explain, many (but not all) retail pharmacies will benefit from Medicaid growth. PBMs, however, will not fare as well. Read on and see if you agree.In early May, Drug Channels Institute will host two live video webinars: Industry Update and COVID-19 Impact: Retail & Specialty Pharmacies (May 1) and Industry Update and COVID-19 Impact: PBMs & Payers (May 8). CLICK HERE TO LEARN MORE AND SIGN UP. DCI will donate 20% of all profits from these events to The Center for Disaster Philanthropy’s COVID-19 Response Fund.Read more » Full Article Health Insurance Exchanges Industry Trends Medicaid PBMs Pharmacy Pharmacy Economics
pr Medication Access During Uncertain Times—Improving Provider Workflows to Help Patients in Need By feeds.feedblitz.com Published On :: Fri, 24 Apr 2020 11:30:00 +0000 Today’s guest post comes from Miranda Gill, Senior Director of Provider Network at CoverMyMeds. Miranda reviews how the pandemic affects the ability of healthcare workers to complete administrative responsibilities like prior authorization. She then outlines how electronic automation is helping patients get needed medications while face-to-face interactions are restricted.Learn more about healthcare IT solutions for providers and patients in CoverMyMeds’ 2020 Medication Access Report, or schedule a virtual meeting.Read more » Full Article Guest Post Sponsored Post
pr Drug Channels News Roundup, April 2020: Drug Pricing Outlook, COVID-19 Data Tracker, Community Oncology Clinics, and My Favorite Chart of 2020 By feeds.feedblitz.com Published On :: Thu, 30 Apr 2020 11:30:00 +0000 Rumor has it that Spring has finally reached our worldwide headquarters here in beautiful downtown Philadelphia. (See photo at right.) While we wait to go outside, please enjoy this month’s selection of noteworthy news:The outlook for drug pricesA outstanding (and free!) resource for tracking COVID-19 daily dataWhat’s up with community oncology practices?Plus, I share my favorite chart of 2020 (so far). P.S. Join the more than 9,200 followers of my curated links to neat stuff at @DrugChannels on Twitter. My recent tweets have highlighted: Prime Therapeutics new gene therapy offering, AmerisourceBergen’s laudable deal with the Justice Department, the Costco/Instacart deal, Rite Aid’s new CEO, clinical trial trends, vaccine pricing, and much more! I have also been tweeting under-the-radar stories about how the coronavirus is affecting drug channels.Tomorrow (May 1), Drug Channels Institute will host the first of two live video webinars: Industry Update and COVID-19 Impact: Retail & Specialty Pharmacies. We'll host the second video webinar—Industry Update and COVID-19 Impact: PBMs & Payers—on May 8. CLICK HERE TO LEARN MORE AND SIGN UP. Contact Paula Fein (paula@drugchannelsinstitute.com) for our special promo codes for multiple viewing sites. DCI will donate 20% of all profits from these events to The Center for Disaster Philanthropy’s COVID-19 Response Fund.Read more » Full Article Buy-and-Bill Costs/Reimbursement Gross-to-Net Bubble Physicians
pr Insurers + PBMs + Specialty Pharmacies + Providers: Will Vertical Consolidation Disrupt Drug Channels in 2020? (rerun) By feeds.feedblitz.com Published On :: Mon, 04 May 2020 11:30:00 +0000 This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Industry Update and COVID-19 Impact: PBMs & Payers. Life was very different when I originally published today’s article. 2020 is not turning out to be quite what any of us expected. However, the pandemic has exposed some intriguing pros and cons of vertical consolidation. Click here to see the original post and comments from December 2019.The largest insurers, PBMs, and specialty pharmacies have now combined into vertically-integrated organizations. As I explain below, these companies have also been rapidly integrating with healthcare providers.I also provide an updated look at these companies and highlight strategies that they are using—or could use—to control the channel. I believe that these insurer / PBM / specialty pharmacy / provider organizations are poised to restructure U.S. drug channels by exerting greater control over patient access, sites of care/dispensing, and pricing.If they can effectively coordinate their sprawling business operations, they will pose a substantial threat of disruption to the existing commercial strategies of pharma companies. Will they succeed by better managing care and costs, or merely by extracting higher profits from our convoluted system?Read more » Full Article Accountable Care Organizations (ACOs) Buy-and-Bill Channel Management Mergers and Acquisitions PBMs Pharmacy Physicians Retail Clinics Specialty Drugs
pr Express Scripts + Prime Therapeutics: Our Four Takeaways From This Market Changing Deal (rerun) By feeds.feedblitz.com Published On :: Tue, 05 May 2020 11:30:00 +0000 This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Industry Update and COVID-19 Impact: PBMs & Payers. I suspect this deal will remain profitable for the participating companies even as COVID-19 alters the US. prescription payer mix. Click here to see the original post and comments from January 2020. National market shares for the largest PBMs in 2019 appears as Exhibit 88 of our 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.P.S. Sorry that today's meme is one day too late for Star Wars day.Just before the holidays, Cigna’s Express Scripts business announced a market-changing deal with Prime Therapeutics. Click here to read the press release.There's been very little written about this transaction, though it has potentially major implications. Below, I share my thoughts on the following topics arising from the deal:Implications for manufacturers and pharmaciesThe role of the secretive Ascent Health Services What this all means for WalgreensWhy the Federal Trade Commission won’t challenge the dealA few weeks ago, I explained why integrated insurer / PBM / specialty pharmacy / provider organizations are poised to restructure U.S. drug channels. The Express Scripts / Prime deal signals that the channel will continue its amazing pace of reinvention.The scale, scope, and interconnectedness of today’s market participants make the system increasingly resistant to massive disruption from either external players like Amazon or a government takeover. Like it or not, the channel will continue to gain power and extract profit. Read on and see if you agree.Read more » Full Article Channel Management Group Purchasing Organizations (GPOs) Industry Trends Mergers and Acquisitions PBMs
pr Why Part D Plans Prefer High List Price Drugs That Raise Costs for Seniors (rerun) By feeds.feedblitz.com Published On :: Wed, 06 May 2020 11:30:00 +0000 This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Industry Update and COVID-19 Impact: PBMs & Payers. Part D reform has faded from the policy debate. This rerun explains why it is still needed. FYI, this is my favorite article from 2020 (so far). Click here to see the original post and comments from January 2020.Our high-list-price/high-rebate system remains a fundamental source of warped incentives and cascading problems within the Medicare Part D program.For proof, check out the previously unpublished data below on market share for products that treat hepatitis C. Despite manufacturers offering products with lower list prices, Medicare Part D plans have rejected the therapeutically identical but lower-priced versions of these drugs.List prices significantly affect seniors’ out of-pocket costs, so Part D plans are needlessly costing many of them thousands of dollars. The federal government's Medicare spending is also unnecessarily higher.Anyone concerned about drug prices should pay close attention to this situation. Part D plans and seniors who don’t need specialty medications are benefiting, while seniors who need treatment with specialty medications are ripped off. Just another day inside the gross-to-net bubble!Read more » Full Article Benefit Design Costs/Reimbursement Gross-to-Net Bubble Medicare Part D PBMs Specialty Drugs
pr Express Scripts vs. CVS Health: Five Lessons From the 2020 Formulary Exclusions and Some Thoughts on Patient Impact (rerun) By feeds.feedblitz.com Published On :: Thu, 07 May 2020 11:30:00 +0000 This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Industry Update and COVID-19 Impact: PBMs & Payers. Today's rerun highlights one of the most effective tactics that PBMs have developed to extract deeper discounts from brand-name drug makers. COVID-19 seems likely shift the U.S. payer mix away from commercial health plans. Expect even tighter formulary management and more restrictions as PBMs work even harder to cut costs for their plan sponsor clients. Click here to see the original post and comments from January 2020.For 2020, the two largest pharmacy benefit managers (PBMs)—Express Scripts and the Caremark business of CVS Health—have again increased the number of drugs they have excluded from their standard formularies. The 2020 formulary exclusion lists are available below for your downloading pleasure.Below, I highlight my key takeaways from the 2020 lists:The number of exclusionsManagement of specialty drugsIndication-based formulariesThe slow adoption of biosimilarsThe PBMs’ patient-unfriendly exclusions in the hepatitis C categoryFormulary exclusions have emerged as a powerful tool for PBMs to gain additional negotiating leverage against manufacturers. The prospect of exclusion leads manufacturers to offer deeper rebates to avoid being cut from the formulary. Exclusions are therefore a key factor behind falling brand-name net drug prices.Read on for a look at this year’s exclusions along with some closing thoughts on what exclusions mean for patients.Read more » Full Article Benefit Design Biosimilars PBMs Specialty Drugs
pr Surprise! Brand-Name Drug Prices Fell in 2019 (rerun) By feeds.feedblitz.com Published On :: Fri, 08 May 2020 11:30:00 +0000 This week, I’m rerunning some popular posts while I prepare for today’s video webinar: Industry Update and COVID-19 Impact: PBMs & Payers. Click here to see the original post and comments from January 2020.Manufacturers recently announced list price increases for many brand-name drugs. The typical increase was about 5%. Judging by recent history, these moderately higher list prices will translate into another year of falling brand-name drug prices in 2020.This surprising conclusion comes from our analysis of SSR Health data on prices for more than 1,000 drugs. Details below.SSR Health data reveal that list prices for brand-name drugs rose by about 5% in 2019. However, net prices (after rebates and discounts) decreased by -3.1%. Drug makers discounted their brand-name drug list prices by an average of 45%.Too many journalists and politicians remain committed to the false narrative of “skyrocketing drug prices.” In 2020, Congress may again take up drug price legislation. Let’s all hope that our country builds its public policies based upon accurate facts and reliable data. Hope has to triumph over experience eventually.Read more » Full Article Costs/Reimbursement Gross-to-Net Bubble Industry Trends PBMs
pr Menopause Predisposes a Fifth of Women to Alzheimer's By www.scientificamerican.com Published On :: Wed, 06 May 2020 13:00:00 GMT Being female is a risk factor for Alzheimer’s. Why? -- Read more on ScientificAmerican.com Full Article Features Mind Neurological Health
pr Comets Prevent Ether from Accumulating in Space By www.scientificamerican.com Published On :: Wed, 06 May 2020 14:30:00 GMT Originally published in January 1859 -- Read more on ScientificAmerican.com Full Article The Sciences Space
pr DIY Tool Lets High Schoolers Practice Gene Editing By www.scientificamerican.com Published On :: Thu, 07 May 2020 12:00:00 GMT With a few dollars, researchers replicated an instrument that typically costs thousands -- Read more on ScientificAmerican.com Full Article Advances Tech Medical & Biotech
pr Cleaner Air Courtesy of Coronavirus Provides Window into a Car-Free Future By www.scientificamerican.com Published On :: Thu, 07 May 2020 15:30:00 GMT With cars off the roads, scientists can study how smog and other types of pollution change -- Read more on ScientificAmerican.com Full Article Sustainability Climate Environment Automotive
pr To Prevent the Next Pandemic, End Unequal Access to Natural Resources By blogs.scientificamerican.com Published On :: Thu, 07 May 2020 16:00:00 GMT Safeguarding public health requires rethinking our relationship to the environment and the inequities that drive its destruction -- Read more on ScientificAmerican.com Full Article Health Environment
pr New Model Predicts Sudden Rogue Waves By www.scientificamerican.com Published On :: Fri, 08 May 2020 10:45:00 GMT Unified theory describes formation of huge, mysterious waves -- Read more on ScientificAmerican.com Full Article Advances The Sciences Physics
pr Rabbit Virus Could Provide Gene Therapy By www.scientificamerican.com Published On :: Fri, 08 May 2020 15:00:00 GMT Originally published in February 1967 -- Read more on ScientificAmerican.com Full Article Medical & Biotech The Sciences Biology
pr ACRO testifies before IRS and Treasury Department on proposed Base Erosion and Anti-Abuse Tax (BEAT) regulation By www.acrohealth.org Published On :: Fri, 29 Mar 2019 14:05:39 +0000 On Monday, March 25, 2019 ACRO provided testimony at a public hearing held by the Internal Revenue Service (IRS) and Treasury Department... Full Article News BEAT IRS Testimony Treasury
pr ACRO offers unique insights on risk-based monitoring of clinical trials, calls for adoption of RBM as a best practice By www.acrohealth.org Published On :: Thu, 16 May 2019 19:01:42 +0000 Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, ACRO this week submitted extensive comments on recent FDA Guidance.Increasing the use of innovative RBM technologies helps make clinical trials safer, more efficient and higher quality. ACRO’s comments offer unique insights into the recent expansion of RBM implementation and call for further increasing the use of these oversight technologies. Full Article News Press Releases digital FDA oversight RBM Risk Based Montoring
pr A Consistent Approach to Risk Based Quality Management: Collaboration is Key By www.acrohealth.org Published On :: Thu, 24 Oct 2019 16:13:05 +0000 Developing, executing and overseeing clinical trials is a complex process. Yet it is essential to gain reliable evidence from clinical trials to... Full Article News Reports
pr Bayer launches pre-filled syringe to administer eye medication Eylea™ in Europe (for specialized target groups only) By www.news.bayer.com Published On :: Wed, 08 Apr 2020 08:00:00 GMT Full Article
pr Methadone to be supplied without new prescription during Covid-19 crisis By www.theguardian.com Published On :: 2020-04-08T05:00:08Z Pharmacists will be allowed to give out medication to patients who have already been receiving itPharmacists are to be allowed to hand out a range of super-strength medicines, including the heroin substitute methadone, without prescription during the Covid-19 crisis, under emergency measures that official drug policy advisers have warned could trigger a spike in drug misuse.The Advisory Council for Misuse of Drugs (ACMD), which makes recommendations to the government on the control of dangerous drugs, was asked by the home secretary to consider the risks of lifting restrictions on certain substances controlled under the Misuse of Drugs Act. Continue reading... Full Article Drugs policy UK news Pharmaceuticals industry Drugs Coronavirus outbreak Politics Science Society
pr AstraZeneca success should prompt review of takeover rules | Nils Pratley By www.theguardian.com Published On :: 2020-04-29T18:31:26Z Firm’s recent success could have been very different had it been bought out by Pfizer in 2014It’s perhaps not surprising that the worth of healthcare companies should emerge during a global pandemic, but we should offer thanks for the UK’s big pharma twins – AstraZeneca and GlaxoSmithKline.The former, with its share price at all-time high, is now jostling with Shell and Unilever for the title of biggest company in the FTSE 100 index. Successful research bets, especially on cancer drugs, have transformed Astra. Continue reading... Full Article Pharmaceuticals industry AstraZeneca GlaxoSmithKline Business Barclays Next
pr Promising drug against Covid-19 unlikely to be available in UK soon By www.theguardian.com Published On :: 2020-04-30T16:50:55Z Trial of remdesivir shows fewer deaths and shorter hospital staysCoronavirus – latest updatesSee all our coronavirus coverageThe first drug against Covid-19 to show promise in trials, reducing the time seriously ill people take to recover in hospital, is unlikely to be available widely in the UK soon, it has emerged.Forty-six people in the UK have received remdesivir as part of the European arm of an international trial. Researchers would like to have given the drug to more patients but did not have the supplies. Related: Coronavirus: what do scientists know about Covid-19 so far? Continue reading... Full Article Medical research Health Pharmaceuticals industry Coronavirus outbreak Science UK news Society
pr AstraZeneca partners with Oxford University to produce Covid-19 vaccine By www.theguardian.com Published On :: 2020-04-30T16:50:57Z Drugmaker will manufacture and distribute vaccine if human trials are successfulCoronavirus – latest updatesSee all our coronavirus coverageAstraZeneca, the Cambridge-based pharmaceutical group, is teaming up with Oxford University to manufacture and distribute a coronavirus vaccine if clinical trials currently under way show it is effective.News of the partnership boosted AstraZeneca’s share price, helping it to become Britain’s most valuable company by market capitalisation. Related: The hunt for a coronavirus vaccine – a perilous and uncertain path Continue reading... Full Article AstraZeneca Pharmaceuticals industry Vaccines and immunisation Coronavirus outbreak UK news Business University of Oxford Research Medical research
pr The promise of an Oxford vaccine reveals how a new Britain could thrive | Will Hutton By www.theguardian.com Published On :: 2020-05-03T06:45:44Z The partnership between AstraZeneca and the Jenner Institute should jolt our industry and banksCoronavirus latest updatesSee all our coronavirus coverageThere was some good news last week. Oxford University’s Jenner Institute announced it was teaming up with AstraZeneca to take a promising prototype of coronavirus vaccine into volume production by the autumn. Of course there are caveats – the institute’s confidence in its vaccine may not be validated by the trials that began last week.Still it was heartening, after so much tragic incompetence, that a British university and a British company could forge a relationship of such potential national importance.The piping through which emergency credit must flow is atrophied and weak Continue reading... Full Article Coronavirus outbreak Infectious diseases Medical research Microbiology Biology Science AstraZeneca University of Oxford Pharmaceuticals industry Banking Business UK news
pr Leading COVID-19 hope remdesivir fails to provide clinical benefit in first randomised trial By www.pharmafile.com Published On :: Fri, 24 Apr 2020 11:29:51 +0000 Gilead’s remdesivir, which has been hailed as one of the few truly promising treatments for COVID-19 at this early stage of the ongoing pandemic, has failed in its first randomised clinical trial, leaked data has revealed. Full Article coronavirus COVID-19 Gilead pharma remdesivir Research and Development Medical Communications
pr Sanofi's Meningococcal Conjugate Vaccine secures FDA approval in patients aged two and up By www.pharmafile.com Published On :: Mon, 27 Apr 2020 11:58:57 +0000 Sanofi’s MedQuadfi Meningococcal Conjugate Vaccine has scored FDA approval for the prevention of invasive meningococcal disease, becoming the first and only product available in the US for this indication in patients of at least two years old. Full Article FDA meningococcal disease MenQuadfi pharma Sanofi US Sales and Marketing
pr NICE backtracks to approve Janssen's Stelara in ulcerative colitis By www.pharmafile.com Published On :: Tue, 28 Apr 2020 10:20:00 +0000 NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which rows back on the Institute’s decision to reject the drug last year. Full Article Janssen NICE Research and Development Stelara ulcerative colitis Manufacturing and Production
pr EU approval for Novartis' Cosentyx in active non-radiographic axial spondyloarthritis By www.pharmafile.com Published On :: Wed, 29 Apr 2020 09:28:04 +0000 Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients. Full Article axial spondyloarthritis Cosentyx EU Novartis pharma Research and Development Sales and Marketing
pr Teva’s cancer drug Bendeka protected from generics until 2031, judge rules By www.pharmafile.com Published On :: Thu, 30 Apr 2020 11:20:42 +0000 A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe on four separate patents, and has delayed them from launching until 2031. Full Article Bendeka Teva Teva and Eagle Business Services
pr FDA approves emergency use of Gilead's remdesivir for hospitalised COVID-19 patients By www.pharmafile.com Published On :: Mon, 04 May 2020 11:31:55 +0000 Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one of the only therapies to do so at this early stage of the pandemic. Now, the FDA has invoked its Emergency Use Authorization powers to approve the drug for the treatment of patients hospitalised with the novel coronavirus. Full Article coronavirus COVID-19 FDA Gilead remdesivir Sales and Marketing
pr Lonza and Moderna enter agreement to mass produce coronavirus vaccine By www.pharmafile.com Published On :: Mon, 04 May 2020 11:43:10 +0000 Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year. Full Article coronavirus COVID-19 Sales and Marketing
pr First French case of COVID-19 occurred in December, a month earlier than previously thought By www.pharmafile.com Published On :: Tue, 05 May 2020 11:46:00 +0000 A French patient who suffered from pneumonia in December actually had COVID-19, it has been revealed. Full Article coronavirus COVID-19 Manufacturing and Production
pr AZ's Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction By www.pharmafile.com Published On :: Wed, 06 May 2020 11:28:32 +0000 The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalisation in adult patients with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction. Full Article AstraZeneca farxiga FDA heart failure Research and Development Sales and Marketing
pr FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14 By www.pharmafile.com Published On :: Thu, 07 May 2020 11:35:49 +0000 The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have a mutation that leads to MET exon 14 skipping (METex14), regardless of whether they have previously received any type of treatment. Full Article Incyte Novartis pharma Tabrecta Sales and Marketing
pr Imperial College London to lead major coronavirus home testing programme By www.pmlive.com Published On :: Fri, 01 May 2020 12:39:45 +0100 Aims to track the progress of the infection across the UK Full Article
pr Roche’s COVID-19 antibody test approved for emergency use in the US By www.pmlive.com Published On :: Mon, 04 May 2020 12:25:11 +0100 Ramps up capacity for testing across the country Full Article